Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 166

Sort by

Sort Order Select

Journal Articles

UnSETtling energy dependence of t(4;14) MM

P. Leif Bergsagel, Marta Chesi

Blood (2024) 144 (3): 244–245.

https://doi.org/10.1182/blood.2024024871

Published: 2024

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2023-174550

Published: 2023

Journal Articles

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

Lorenzo Lindo, Erin Meermeier, Lauren H Wilkinson, Silvia Selleri, Mehdi Arbabi Ghahroudi, Scott McComb, P. Leif Bergsagel, Marta Chesi, Laura Evgin, Daniel D Waller, Kevin A Hay

Blood (2023) 142 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2023-178821

Published: 2023

Journal Articles

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Sinto Sebastian Chirackal, Taro Hitosugi, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2023-189785

Published: 2023

Journal Articles

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Yan Cheng, Fumou Sun, Wancheng Guo, Hongwei Xu, Prasanth Viswanathan, Mark Manzano, Eric Siegel, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Marta Chesi, P. Leif Bergsagel, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3309.

https://doi.org/10.1182/blood-2023-187001

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2023) 142 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2023-173970

Published: 2023

Journal Articles

Beyond the Primary: Unveiling the Prognostic Value of Secondary Cytogenetic Abnormalities in Multiple Myeloma

Rodrigo Fonseca, Mariano Arribas, Gregory Ahmann, Janna C Castro, Erin E Wiedmeier-Nutor, Linda Banovic Baughn, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2023-190701

Published: 2023

Journal Articles

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Laura Lucia Cogrossi, Matteo Grioni, Paola Zordan, Benedetta Mattorre, Marco Lorenzoni, Greta Meregalli, Anna Policastro, Roberto Ferrarese, Nicola Clementi, Sofia Sisti, Nicasio Mancini, Marta Chesi, P. Leif Bergsagel, Matteo Bellone

Blood (2023) 142 (Supplement 1): 754.

https://doi.org/10.1182/blood-2023-180145

Published: 2023

Journal Articles

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Blood (2023) 142 (Supplement 1): 6927.

https://doi.org/10.1182/blood-2023-189683

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Radhika Bansal, Sikander Ailawadhi, Jeremy T. Larsen, Morie A Gertz, Matthew A. Hathcock, David Dingli, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M Warsame, Moritz Binder, Ricardo D Parrondo, Rafael Fonseca, P. Leif Bergsagel, Shaji K Kumar, Yi Lin

Blood (2022) 140 (Supplement 1): 1862–1864.

https://doi.org/10.1182/blood-2022-166662

Published: 2022

Journal Articles

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Cecilia Bonolo De Campos, James B Smadbeck, Mariano Arribas, Neeraj Sharma, Gregory J Ahmann, Shaji K Kumar, A. Keith Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan Asmann, Linda B. Baughn, Esteban Braggio

Blood (2022) 140 (Supplement 1): 7180–7181.

https://doi.org/10.1182/blood-2022-170749

Published: 2022

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Yael Kusne, Rodrigo Fonseca, Mariano Arribas, Molly Klanderman, Julia E. Wiedmeier, Craig B. Reeder, Jeremy T. Larsen, P. Leif Bergsagel, Julie L Rosenthal, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7224–7225.

https://doi.org/10.1182/blood-2022-166668

Published: 2022

Journal Articles

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Yuan Xiao Zhu, Gregory J Ahmann, Laura Ann Bruins, Mariano Arribas, Xianfeng Chen, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca, Lisa M. Rimsza

Blood (2022) 140 (Supplement 1): 4187–4188.

https://doi.org/10.1182/blood-2022-157316

Published: 2022

Journal Articles

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Francesco Maura, David Coffey, Esteban Braggio, Caleb K Stein, Meaghen E Sharik, Megan T Du, Bachisio Ziccheddu, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, Marta Chesi

Blood (2022) 140 (Supplement 1): 1540–1541.

https://doi.org/10.1182/blood-2022-166614

Published: 2022

Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood (2022) 140 (Supplement 1): 10017–10019.

https://doi.org/10.1182/blood-2022-167181

Published: 2022

NARROW

UnSETtling energy dependence of t(4;14) MM

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Beyond the Primary: Unveiling the Prognostic Value of Secondary Cytogenetic Abnormalities in Multiple Myeloma

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Genomic profiling for clinical decision making in lymphoid neoplasms

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only